Heterocyclic Compound AMPA Receptor Potentiation via Structural Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds do not effectively act as AMPA receptor potentiators, which are crucial for treating psychiatric diseases, neurodegenerative disorders, and cognitive disorders, as they lack the necessary potency and specificity to modulate AMPA receptor activity effectively.
Innovation Solution
A novel heterocyclic compound represented by formula (I) and its salts, which are designed to potentiate AMPA receptors by specifically interacting with the receptor subunits, enhancing their activity and providing therapeutic benefits for depression, schizophrenia, Alzheimer's disease, and attention deficit hyperactivity disorder.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing heterocyclic compounds are used, then the structural complexity is reduced, but the AMPA receptor potentiating activity and specificity are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters such as substituent types (halogen, hydroxy, alkyl, alkoxy), ring sizes (5-8 membered heterocycles), and connectivity patterns in formula (I) to optimize AMPA receptor binding affinity and potentiating activity while maintaining manageable structural complexity through defined structural frameworks
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and heteroatom configurations at particular positions within the molecular structure to enhance interaction with specific AMPA receptor subunits (GluR1, GluR2, GluR3, GluR4), thereby improving receptor potentiating activity at critical binding sites
2Reliability
If existing compounds are used, then the ease of manufacture is maintained, but the therapeutic efficacy for psychiatric and neurodegenerative diseases is insufficient
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules (ring A, ring B, ring D, connecting groups W and L) that can be synthesized separately and then assembled, allowing for optimized therapeutic efficacy while maintaining reasonable manufacturing complexity through modular construction
Solution Approach 2:
The patent applies the intermediary principle by introducing spacer groups (L with 1-8 atoms) and connecting moieties (W with C1-3 or C2-3 atoms) that facilitate the assembly of complex heterocyclic structures from simpler precursors, thereby improving therapeutic efficacy without excessively complicating the synthesis process
Data Source
AI summary
Provided is a compound represented by the formula (I):wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.